$LLY, Price correction?
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Positive:
Negative:
Very strong bullish trend, it is expecting a price correction after this stock should follow
Positive:
- Yields high return on invested capital
- Has raised its dividend for 8 consecutive years
- 13 analysts have revised their earnings upwards for the upcoming period
- Prominent player in the Pharmaceuticals industry
- Cash flows can sufficiently cover interest payments
- High return over the last year
- An analyst from Morgan Stanley maintained Eli Lilly (NYSE: LLY) at 'overweight' with a price target of $640.00 from a prior price target of $617.00.
Negative:
- Trading at a high earnings multiple
- Corporate insiders Sold shares worth 21.3B in the past 3 months
- Hedge funds Sold 789.5K shares in the past quarter
Very strong bullish trend, it is expecting a price correction after this stock should follow
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.